Indeed, results of the DESTINY-PanTumor02 trial, which investigated the efficacy of T-DXd in patients with HER2-positive solid tumors, demonstrated clinically meaningful progression-free survival and overall survival in patients with unresectable HER2-positive cancers.2 This evidence concerns the gene ERBB2 and cancer.